{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T08:58:10Z","timestamp":1793350690351,"version":"4.5.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100007270","name":"University of Michigan","doi-asserted-by":"publisher","award":["N035800"],"award-info":[{"award-number":["N035800"]}],"id":[{"id":"10.13039\/100007270","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Michigan Strategic Fund"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Cancer"],"DOI":"10.1038\/s43018-026-01158-7","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T09:03:46Z","timestamp":1777367026000},"page":"857-875","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Dual targeting of PI3K\u03b3 and STING overcomes regulatory B cell- and myeloid cell-driven immune suppression in pancreatic cancer"],"prefix":"10.1038","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2378-6408","authenticated-orcid":false,"given":"Chengyi","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahamadou","family":"Djibo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linqi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meilin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanning","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongwei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihong","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana R.","family":"Xavier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minal","family":"Nenwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8337-220X","authenticated-orcid":false,"given":"Bo","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1892-1548","authenticated-orcid":false,"given":"Vaibhav","family":"Sahai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8999-2282","authenticated-orcid":false,"given":"Deepak","family":"Nagrath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie L.","family":"Lucas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3349-4281","authenticated-orcid":false,"given":"Matthias P.","family":"Wymann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5233-3734","authenticated-orcid":false,"given":"Wei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6428-428X","authenticated-orcid":false,"given":"Lawrence","family":"Fong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6406-2126","authenticated-orcid":false,"given":"Duxin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"key":"1158_CR1","first-page":"7","volume":"75","author":"BW Corn","year":"2025","unstructured":"Corn, B. W. & Feldman, D. B. Cancer statistics, 2025: a hinge moment for optimism to morph into hope?. CA Cancer J. Clin. 75, 7\u20139 (2025).","journal-title":"CA Cancer J. Clin."},{"key":"1158_CR2","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy, T. et al. FOLFIRINOX versus Gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 364, 1817\u20131825 (2011).","journal-title":"N. Engl. J. Med."},{"key":"1158_CR3","doi-asserted-by":"publisher","first-page":"4548","DOI":"10.1200\/JCO.2011.36.5742","volume":"29","author":"DD Von Hoff","year":"2011","unstructured":"Von Hoff, D. D. et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I\/II trial. J. Clin. Oncol. 29, 4548\u20134554 (2011).","journal-title":"J. Clin. Oncol."},{"key":"1158_CR4","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.ccell.2020.08.004","volume":"38","author":"AS Bear","year":"2020","unstructured":"Bear, A. S., Vonderheide, R. H. & O\u2019Hara, M. H. Challenges and opportunities for pancreatic cancer immunotherapy. Cancer Cell 38, 788\u2013802 (2020).","journal-title":"Cancer Cell"},{"key":"1158_CR5","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.3390\/ijms19113505","volume":"19","author":"S Macherla","year":"2018","unstructured":"Macherla, S. et al. Emerging role of immune checkpoint blockade in pancreatic cancer. Int. J. Mol. Sci. 19, 3505 (2018).","journal-title":"Int. J. Mol. Sci."},{"key":"1158_CR6","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1038\/s41590-020-0761-y","volume":"21","author":"J Leinwand","year":"2020","unstructured":"Leinwand, J. & Miller, G. Regulation and modulation of antitumor immunity in pancreatic cancer. Nat. Immunol. 21, 1152\u20131159 (2020).","journal-title":"Nat. Immunol."},{"key":"1158_CR7","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/s41571-020-0363-5","volume":"17","author":"WJ Ho","year":"2020","unstructured":"Ho, W. J., Jaffee, E. M. & Zheng, L. The tumour microenvironment in pancreatic cancer\u2014clinical challenges and opportunities. Nat. Rev. Clin. Oncol. 17, 527\u2013540 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1158_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100744","volume":"3","author":"B Mirlekar","year":"2022","unstructured":"Mirlekar, B. et al. Balance between immunoregulatory B cells and plasma cells drives pancreatic tumor immunity. Cell Rep. Med. 3, 100744 (2022).","journal-title":"Cell Rep. Med."},{"key":"1158_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1152551","volume":"14","author":"ZN Senturk","year":"2023","unstructured":"Senturk, Z. N., Akdag, I., Deniz, B. & Sayi-Yazgan, A. Pancreatic cancer: emerging field of regulatory B-cell-targeted immunotherapies. Front. Immunol. 14, 1152551 (2023).","journal-title":"Front. Immunol."},{"key":"1158_CR10","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1111\/1440-1681.13317","volume":"47","author":"D-N Tong","year":"2020","unstructured":"Tong, D.-N. et al. Characterization of B cell-mediated PD-1\/PD-L1 interaction in pancreatic cancer patients. Clin. Exp. Pharmacol. Physiol. 47, 1342\u20131349 (2020).","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"1158_CR11","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/s41586-022-05254-3","volume":"610","author":"S Li","year":"2022","unstructured":"Li, S. et al. STING-induced regulatory B cells compromise NK function in cancer immunity. Nature 610, 373\u2013380 (2022).","journal-title":"Nature"},{"key":"1158_CR12","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1053\/j.gastro.2018.12.038","volume":"156","author":"VP Balachandran","year":"2019","unstructured":"Balachandran, V. P., Beatty, G. L. & Dougan, S. K. Broadening the impact of immunotherapy to pancreatic cancer: challenges and opportunities. Gastroenterology 156, 2056\u20132072 (2019).","journal-title":"Gastroenterology"},{"key":"1158_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.215694","volume":"538","author":"H Chamma","year":"2022","unstructured":"Chamma, H., Vila, I. K., Taffoni, C., Turtoi, A. & Laguette, N. Activation of STING in the pancreatic tumor microenvironment: a novel therapeutic opportunity. Cancer Lett. 538, 215694 (2022).","journal-title":"Cancer Lett."},{"key":"1158_CR14","doi-asserted-by":"publisher","first-page":"1777624","DOI":"10.1080\/2162402X.2020.1777624","volume":"9","author":"J Le Naour","year":"2020","unstructured":"Le Naour, J., Zitvogel, L., Galluzzi, L., Vacchelli, E. & Kroemer, G. Trial watch: STING agonists in cancer therapy. Oncoimmunology 9, 1777624 (2020).","journal-title":"Oncoimmunology"},{"key":"1158_CR15","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1038\/s41423-022-00952-4","volume":"19","author":"Y Wang","year":"2022","unstructured":"Wang, Y., Geller, A. E. & Yan, J. Unexpected Breg-NK crosstalk in STING agonist therapy. Cell. Mol. Immunol. 19, 1330\u20131332 (2022).","journal-title":"Cell. Mol. Immunol."},{"key":"1158_CR16","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/nrc3860","volume":"15","author":"LM Thorpe","year":"2015","unstructured":"Thorpe, L. M., Yuzugullu, H. & Zhao, J. J. PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nat. Rev. Cancer 15, 7\u201324 (2015).","journal-title":"Nat. Rev. Cancer"},{"key":"1158_CR17","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nature19834","volume":"539","author":"MM Kaneda","year":"2016","unstructured":"Kaneda, M. M. et al. PI3K\u03b3 is a molecular switch that controls immune suppression. Nature 539, 437\u2013442 (2016).","journal-title":"Nature"},{"key":"1158_CR18","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/nature20554","volume":"539","author":"O De Henau","year":"2016","unstructured":"De Henau, O. et al. Overcoming resistance to checkpoint blockade therapy by targeting PI3K\u03b3 in myeloid cells. Nature 539, 443\u2013447 (2016).","journal-title":"Nature"},{"key":"1158_CR19","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/nri1056","volume":"3","author":"K Okkenhaug","year":"2003","unstructured":"Okkenhaug, K. & Vanhaesebroeck, B. PI3K in lymphocyte development, differentiation and activation. Nat. Rev. Immunol. 3, 317\u2013330 (2003).","journal-title":"Nat. Rev. Immunol."},{"key":"1158_CR20","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.chembiol.2025.01.004","volume":"32","author":"HY Zhao","year":"2025","unstructured":"Zhao, H. Y. et al. An oral tricyclic STING agonist suppresses tumor growth through remodeling of the immune microenvironment. Cell Chem. Biol. 32, 280\u2013290 e214 (2025).","journal-title":"Cell Chem. Biol."},{"key":"1158_CR21","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abl3649","volume":"14","author":"Y Song","year":"2022","unstructured":"Song, Y. et al. Albumin nanoparticle containing a PI3K\u03b3 inhibitor and paclitaxel in combination with \u03b1-PD1 induces tumor remission of breast cancer in mice. Sci. Transl. Med. 14, eabl3649 (2022).","journal-title":"Sci. Transl. Med."},{"key":"1158_CR22","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/s41573-019-0043-2","volume":"18","author":"C Vanpouille-Box","year":"2019","unstructured":"Vanpouille-Box, C., Hoffmann, J. A. & Galluzzi, L. Pharmacological modulation of nucleic acid sensors\u2014therapeutic potential and persisting obstacles. Nat. Rev. Drug Discov. 18, 845\u2013867 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1158_CR23","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abn6612","volume":"8","author":"B Jneid","year":"2023","unstructured":"Jneid, B. et al. Selective STING stimulation in dendritic cells primes antitumor T\u2009cell responses. Sci. Immunol. 8, eabn6612 (2023).","journal-title":"Sci. Immunol."},{"key":"1158_CR24","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.jconrel.2023.03.047","volume":"357","author":"X Sun","year":"2023","unstructured":"Sun, X., Zhou, X., Lei, Y. L. & Moon, J. J. Unlocking the promise of systemic STING agonist for cancer immunotherapy. J. Control. Release 357, 417\u2013421 (2023).","journal-title":"J. Control. Release"},{"key":"1158_CR25","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1038\/nrd3248","volume":"9","author":"V Brinkmann","year":"2010","unstructured":"Brinkmann, V. et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat. Rev. Drug Discov. 9, 883\u2013897 (2010).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1158_CR26","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.cell.2020.02.015","volume":"180","author":"Y Lu","year":"2020","unstructured":"Lu, Y. et al. Complement signals determine opposite effects of B\u2009cells in chemotherapy-induced immunity. Cell 180, 1081\u20131097 (2020).","journal-title":"Cell"},{"key":"1158_CR27","doi-asserted-by":"publisher","DOI":"10.1126\/science.aba6098","volume":"369","author":"B-S Pan","year":"2020","unstructured":"Pan, B.-S. et al. An orally available non-nucleotide STING agonist with antitumor activity. Science 369, eaba6098 (2020).","journal-title":"Science"},{"key":"1158_CR28","doi-asserted-by":"publisher","first-page":"eaay9013","DOI":"10.1126\/scitranslmed.aay9013","volume":"12","author":"W Li","year":"2020","unstructured":"Li, W. et al. cGAS-STING-mediated DNA sensing maintains CD8+ T cell stemness and promotes antitumor T cell therapy. Sci. Transl. Med. 12, eaay9013 (2020).","journal-title":"Sci. Transl. Med."},{"key":"1158_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-1087-y","volume":"18","author":"Y Zhu","year":"2019","unstructured":"Zhu, Y. et al. STING: a master regulator in the cancer-immunity cycle. Mol. Cancer 18, 152 (2019).","journal-title":"Mol. Cancer"},{"key":"1158_CR30","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1126\/science.1232458","volume":"339","author":"L Sun","year":"2013","unstructured":"Sun, L., Wu, J., Du, F., Chen, X. & Chen, Z. J. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 339, 786\u2013791 (2013).","journal-title":"Science"},{"key":"1158_CR31","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1038\/nature08476","volume":"461","author":"H Ishikawa","year":"2009","unstructured":"Ishikawa, H., Ma, Z. & Barber, G. N. STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. Nature 461, 788\u2013792 (2009).","journal-title":"Nature"},{"key":"1158_CR32","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1038\/nri3921","volume":"15","author":"GN Barber","year":"2015","unstructured":"Barber, G. N. STING: infection, inflammation and cancer. Nat. Rev. Immunol. 15, 760\u2013770 (2015).","journal-title":"Nat. Rev. Immunol."},{"key":"1158_CR33","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41580-020-0244-x","volume":"21","author":"K-P Hopfner","year":"2020","unstructured":"Hopfner, K.-P. & Hornung, V. Molecular mechanisms and cellular functions of cGAS\u2013STING signalling. Nat. Rev. Mol. Cell Biol. 21, 501\u2013521 (2020).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"1158_CR34","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s10555-010-9223-6","volume":"29","author":"DG DeNardo","year":"2010","unstructured":"DeNardo, D. G., Andreu, P. & Coussens, L. M. Interactions between lymphocytes and myeloid cells regulate pro-versus anti-tumor immunity. Cancer Metastasis Rev. 29, 309\u2013316 (2010).","journal-title":"Cancer Metastasis Rev."},{"key":"1158_CR35","doi-asserted-by":"publisher","first-page":"1900311","DOI":"10.1002\/adbi.201900311","volume":"5","author":"J Xiong","year":"2021","unstructured":"Xiong, J., Wang, H. & Wang, Q. Suppressive myeloid cells shape the tumor immune microenvironment. Adv. Biol. 5, 1900311 (2021).","journal-title":"Adv. Biol."},{"key":"1158_CR36","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/s41573-022-00520-5","volume":"21","author":"A Mantovani","year":"2022","unstructured":"Mantovani, A., Allavena, P., Marchesi, F. & Garlanda, C. Macrophages as tools and targets in cancer therapy. Nat. Rev. Drug Discov. 21, 799\u2013820 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1158_CR37","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/j.1600-065X.2010.00934.x","volume":"237","author":"M Werner","year":"2010","unstructured":"Werner, M., Hobeika, E. & Jumaa, H. Role of PI3K in the generation and survival of B cells. Immunol. Rev. 237, 55\u201371 (2010).","journal-title":"Immunol. Rev."},{"key":"1158_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1115244","volume":"14","author":"F Olayinka-Adefemi","year":"2023","unstructured":"Olayinka-Adefemi, F., Hou, S. & Marshall, A. J. Dual inhibition of phosphoinositide 3-kinases delta and gamma reduces chronic B cell activation and autoantibody production in a mouse model of lupus. Front. Immunol. 14, 1115244 (2023).","journal-title":"Front. Immunol."},{"key":"1158_CR39","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/nri.2016.93","volume":"16","author":"CL Lucas","year":"2016","unstructured":"Lucas, C. L., Chandra, A., Nejentsev, S., Condliffe, A. M. & Okkenhaug, K. PI3K\u03b4 and primary immunodeficiencies. Nat. Rev. Immunol. 16, 702\u2013714 (2016).","journal-title":"Nat. Rev. Immunol."},{"key":"1158_CR40","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1189\/jlb.0809585","volume":"87","author":"S Beer-Hammer","year":"2010","unstructured":"Beer-Hammer, S. et al. The catalytic PI3K isoforms p110\u03b3 and p110\u03b4 contribute to B cell development and maintenance, transformation, and proliferation. J. Leukoc. Biol. 87, 1083\u20131095 (2010).","journal-title":"J. Leukoc. Biol."},{"key":"1158_CR41","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/s41577-022-00701-8","volume":"22","author":"SM Lanahan","year":"2022","unstructured":"Lanahan, S. M., Wymann, M. P. & Lucas, C. L. The role of PI3Kgamma in the immune system: new insights and translational implications. Nat. Rev. Immunol. 22, 687\u2013700 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"1158_CR42","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/s41577-022-00701-8","volume":"22","author":"SM Lanahan","year":"2022","unstructured":"Lanahan, S. M., Wymann, M. P. & Lucas, C. L. The role of PI3K\u03b3 in the immune system: new insights and translational implications. Nat. Rev. Immunol. 22, 687\u2013700 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"1158_CR43","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1038\/s41590-024-01890-1","volume":"25","author":"SM Lanahan","year":"2024","unstructured":"Lanahan, S. M. et al. PI3K\u03b3 in B cells promotes antibody responses and generation of antibody-secreting cells. Nat. Immunol. 25, 1422\u20131431 (2024).","journal-title":"Nat. Immunol."},{"key":"1158_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12311-5","volume":"10","author":"AJ Takeda","year":"2019","unstructured":"Takeda, A. J. et al. Human PI3K\u03b3 deficiency and its microbiota-dependent mouse model reveal immunodeficiency and tissue immunopathology. Nat. Commun. 10, 4364 (2019).","journal-title":"Nat. Commun."},{"key":"1158_CR45","first-page":"14.39.11","volume":"73","author":"JW Lee","year":"2016","unstructured":"Lee, J. W., Komar, C. A., Bengsch, F., Graham, K. & Beatty, G. L. Genetically engineered mouse models of pancreatic cancer: the KPC model (LSL-Kras(G12D\/+);LSL-Trp53(R172H\/+);Pdx-1-Cre), its variants, and their application in immuno-oncology drug discovery. Curr. Protoc. Pharmacol. 73, 14.39.11\u201314.39.20 (2016).","journal-title":"Curr. Protoc. Pharmacol."},{"key":"1158_CR46","first-page":"234","volume":"59","author":"EV Paster","year":"2009","unstructured":"Paster, E. V., Villines, K. A. & Hickman, D. L. Endpoints for mouse abdominal tumor models: refinement of current criteria. Comp. Med. 59, 234\u2013241 (2009).","journal-title":"Comp. Med."},{"key":"1158_CR47","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1038\/sj.bjc.6605642","volume":"102","author":"P Workman","year":"2010","unstructured":"Workman, P. et al. Guidelines for the welfare and use of animals in cancer research. Br. J. Cancer 102, 1555\u20131577 (2010).","journal-title":"Br. J. Cancer"},{"key":"1158_CR48","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S0022-1759(98)00204-X","volume":"223","author":"MB Lutz","year":"1999","unstructured":"Lutz, M. B. et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J. Immunol. Methods 223, 77\u201392 (1999).","journal-title":"J. Immunol. Methods"},{"key":"1158_CR49","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.immuni.2018.06.006","volume":"49","author":"J Li","year":"2018","unstructured":"Li, J. et al. Tumor cell-intrinsic factors underlie heterogeneity of immune cell infiltration and response to immunotherapy. Immunity 49, 178\u2013193 (2018).","journal-title":"Immunity"},{"key":"1158_CR50","doi-asserted-by":"publisher","first-page":"20447","DOI":"10.1073\/pnas.1009968107","volume":"107","author":"IL Grigorova","year":"2010","unstructured":"Grigorova, I. L., Panteleev, M. & Cyster, J. G. Lymph node cortical sinus organization and relationship to lymphocyte egress dynamics and antigen exposure. Proc. Natl Acad. Sci. USA 107, 20447\u201320452 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1158_CR51","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.cell.2014.10.010","volume":"159","author":"N Renier","year":"2014","unstructured":"Renier, N. et al. iDISCO: a simple, rapid method to immunolabel large tissue samples for volume imaging. Cell 159, 896\u2013910 (2014).","journal-title":"Cell"},{"key":"1158_CR52","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/s41563-021-01085-1","volume":"21","author":"CR Below","year":"2022","unstructured":"Below, C. R. et al. A microenvironment-inspired synthetic three-dimensional model for pancreatic ductal adenocarcinoma organoids. Nat. Mater. 21, 110\u2013119 (2022).","journal-title":"Nat. Mater."},{"key":"1158_CR53","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.cell.2014.12.021","volume":"160","author":"SF Boj","year":"2015","unstructured":"Boj, S. F. et al. Organoid models of human and mouse ductal pancreatic cancer. Cell 160, 324\u2013338 (2015).","journal-title":"Cell"},{"key":"1158_CR54","doi-asserted-by":"publisher","first-page":"2708","DOI":"10.1038\/emboj.2013.204","volume":"32","author":"M Huch","year":"2013","unstructured":"Huch, M. et al. Unlimited in vitro expansion of adult bi-potent pancreas progenitors through the Lgr5\/R-spondin axis. EMBO J. 32, 2708\u20132721 (2013).","journal-title":"EMBO J."},{"key":"1158_CR55","doi-asserted-by":"publisher","first-page":"9584","DOI":"10.1021\/acsnano.3c13038","volume":"18","author":"C Li","year":"2024","unstructured":"Li, C. et al. Antigen-clustered nanovaccine achieves long-term tumor remission by promoting B\/CD 4 T\u2009cell crosstalk. ACS Nano 18, 9584\u20139604 (2024).","journal-title":"ACS Nano"},{"key":"1158_CR56","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s41551-025-01344-5","volume":"9","author":"Y Zhang","year":"2025","unstructured":"Zhang, Y. et al. Small circular RNAs as vaccines for cancer immunotherapy. Nat. Biomed. Eng. 9, 249\u2013267 (2025).","journal-title":"Nat. Biomed. Eng."},{"key":"1158_CR57","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."},{"key":"1158_CR58","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu, G., Wang, L. G., Han, Y. & He, Q. Y. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS 16, 284\u2013287 (2012).","journal-title":"OMICS"}],"container-title":["Nature Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01158-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01158-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01158-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T14:02:00Z","timestamp":1780063320000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01158-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":58,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["1158"],"URL":"https:\/\/doi.org\/10.1038\/s43018-026-01158-7","relation":{},"ISSN":["2662-1347"],"issn-type":[{"value":"2662-1347","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,28]]},"assertion":[{"value":"9 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The University of Michigan has submitted a patent application (PCT\/US2024\/053672, Dual functioning immune modulating compounds, formulations, and uses thereof), in which some authors (D.S., C.L., W.G., B.W., M.W., M.H., H.Z., S.M., M.D., Z.L., H.W. and F.K.) are listed as inventors. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}